Covis logo.png
COVIS PHARMA GROUP annonce les premières données d'innocuité et d'efficacité d'une étude de phase 3 contrôlée par placebo sur la COVID-19 utilisant du corticostéroïde inhalé (ciclésonide)
15 avr. 2021 14h14 HE | AMAG Pharmaceuticals, Inc.
ZOUG, Suisse, 15 avr. 2021 (GLOBE NEWSWIRE) -- Covis Pharma Group (la « Société »), société pharmaceutique spécialisée mondiale qui commercialise des solutions thérapeutiques pour les patients...
Covis logo.png
COVIS PHARMA GROUP gibt wichtigste Sicherheits- und Wirksamkeitsdaten einer placebokontrollierten Phase-3-Studie zu COVID-19 mit inhalativem Kortikosteroid (Ciclesonid) bekannt
15 avr. 2021 14h14 HE | AMAG Pharmaceuticals, Inc.
ZUG, Schweiz, April 15, 2021 (GLOBE NEWSWIRE) -- Die Covis Pharma Group (das „Unternehmen“), ein globales spezialisiertes Pharmaunternehmen, das therapeutische Lösungen für Patienten mit...
Covis logo.png
COVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3 Placebo-Controlled COVID-19 Study Using Inhaled Corticosteroid (ciclesonide)
15 avr. 2021 07h00 HE | Covis Pharma Group
ZUG, Switzerland, April 15, 2021 (GLOBE NEWSWIRE) -- Covis Pharma Group (the “Company”), a global specialty pharmaceutical company that markets therapeutic solutions for patients with...
AMAG Pharmaceuticals logo
AMAG Pharmaceuticals Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection)
14 déc. 2020 08h47 HE | AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. has submitted its response to the FDA’s Notice of Opportunity for a Hearing (“NOOH”) regarding the Agency’s proposal to...
AMAG Pharmaceuticals logo
AMAG Pharmaceuticals Requests Hearing to Maintain Makena® (Hydroxyprogesterone Caproate Injection) as a Treatment Option for Clinically Indicated Pregnant Patients
14 oct. 2020 16h11 HE | AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Drug...
AMAG Pharmaceuticals logo
AMAG Pharmaceuticals Provides Update on FDA’s Proposal Regarding Makena® (Hydroxyprogesterone Caproate Injection)
05 oct. 2020 21h05 HE | AMAG Pharmaceuticals, Inc.
The product remains on the marketAMAG has 15 days to respond to the FDAAMAG continues to expect its recently announced tender offer and merger to close in November 2020 WALTHAM, Mass., Oct. 05, 2020...
AMAG Pharmaceuticals logo
Covis Group Announces Agreement to Acquire AMAG Pharmaceuticals
01 oct. 2020 10h45 HE | AMAG Pharmaceuticals, Inc.
Addition of AMAG’s category leading treatments positions Covis to become a global market leader of therapeutic solutions for life-threatening conditions and chronic illnesses Covis will commence a...
AMAG Pharmaceuticals logo
AMAG Pharmaceuticals to Participate in H.C. Wainwright 22nd Annual Global Investment Conference
09 sept. 2020 08h00 HE | AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Scott Myers, Chief Executive Officer, and Brian Piekos, Chief Financial Officer,...
AMAG Pharmaceuticals logo
AMAG Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Corporate Update
06 août 2020 07h00 HE | AMAG Pharmaceuticals, Inc.
Financial guidance reissued to include EBITDA-positive projection for second-half 2020 Strategic shift and momentum build through recent business development activities Brian Piekos promoted to...
AMAG Pharmaceuticals logo
AMAG Pharmaceuticals to Host Second Quarter FY 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020
28 juil. 2020 08h00 HE | AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its second quarter 2020 financial results will be released on Thursday, August 6,...